Drug Type Antibody drug conjugate (ADC), T cell engagers (TCE) |
Synonyms XBH 111, XBH111 |
Target |
Action inhibitors |
Mechanism CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Solid tumor | Discovery | United States | 01 Dec 2025 | |
| Solid tumor | Discovery | China | 01 Dec 2025 |






